drugset / Trial / NCT01814085

A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression

NCT01814085

Phase 4 Completed 225 enrolled Xian-Janssen Pharmaceutical Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of escitalopram treatment in participants with severe major depressive disorder (MDD \[marked depression appearing in the involution period and characterized by hallucinations, delusions, paranoia, and agitation\]).

Timeline

Start
2010-02
Primary completion
2012-02
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule 10 mg Oral
Subject Escitalopram Small molecule 20 mg Oral